// App-Quantinova.ai

P579 : A PHASE 4 STUDY OF FRACTIONATED GEMTUZUMAB OZOGAMICIN ON QT INTERVAL AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA

Researchers

Presenter

  • Pau Montesinos

Principal Investigators

  • Vamsi Kota

  • Joseph Brandwein

  • Pierre Bousset

  • Rebecca J Benner

  • Erik Vandendries

  • Mary Frances McMullin

Medical Centers

  • Pfizer Inc,Cambridge,United States

  • Hematology,Hospital Universitario y Politécnico La Fe,Valencia,Spanien

  • Pfizer Inc., Groton, United States

  • Department of Medicine: Hematology and Oncology, Medical College of Georgia, Augusta University,Augusta,Stati Uniti

  • Department of Medicine, Faculty of Medicine and Dentistry,University of Alberta,Edmonton,Canada

  • Hematology,Hospital Universitario y Politécnico La Fe,Valencia,Spanien

  • Hematology,Hospital Universitario y Politécnico La Fe,Valencia,Spanien

  • Pfizer Inc,Cambridge,Verenigde Staten

  • School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom

  • Pfizer Inc., Paris, France

  • Pfizer Inc.,Cambridge,Stati Uniti

  • Pfizer Inc.,Paris,Франция

  • Pfizer Inc., Paris, France

  • Department of Medicine, Faculty of Medicine and Dentistry,University of Alberta,Edmonton,Canada

  • School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom

  • Department of Medicine: Hematology and Oncolog

  • Pfizer Inc.,Paris,Frankreich

  • Pfizer Inc., Paris, France

  • Pfizer Inc., Cambridge, MA

  • Pfizer Inc.,Groton,Vereinigte Staaten

  • Pfizer Inc.,Paris,Frankreich

  • Department of Hematology,Hospital Universitario i Politècnico l

  • Pfizer Inc.,Groton,Estados Unidos

  • Epizyme, Inc.,Cambridge,Estados Unidos

  • Pfizer Inc.,Groton,Vereinigte Staaten

  • Pfizer Inc., Paris, France

  • Pfizer Inc,Cambridge,États-unis

  • School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom

  • Department of Medicine: Hematology and Oncology, Medical College of Georgia, Augusta University,Augusta,Stati Uniti

  • School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom

  • Pfizer Inc.,Groton,Stati Uniti

  • Pfizer Inc.,Groton,États-unis

  • Hematology, Hospital Universitario La Fe, Valencia, Spain

  • Department of Medicine: Hematology and Oncology, Medical College of Georgia, Augusta University,Augusta,Stati Uniti

  • Pfizer Inc.,Groton,USA

  • Pfizer Inc,Cambridge,Verenigde Staten

Locations

  • Venezuela

  • Spain

  • United States

  • Canada

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Hepatic veno-occlusive disease with immunodeficiency

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Gemtuzumab ozogamicin

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • IV

Study Id's

  • NCT03727750

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved